Medicus Pharma (NASDAQ:MDCX) Cut to “Hold” at Brookline Capital Markets

Brookline Capital Markets downgraded shares of Medicus Pharma (NASDAQ:MDCX) from a buy rating to a hold rating in a report released on Wednesday, Marketbeat.com reports.

Several other brokerages have also recently issued reports on MDCX. Weiss Ratings upgraded shares of Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Wall Street Zen lowered Medicus Pharma from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 8th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Medicus Pharma in a research note on Monday, September 14th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $450.00.

Medicus Pharma Stock Performance

NASDAQ MDCX opened at $1.95 on Wednesday. The company has a market capitalization of $3.74 million, a PE ratio of -0.02 and a beta of 0.80. The business’s fifty day moving average is $5.12 and its 200 day moving average is $20.14. Medicus Pharma has a fifty-two week low of $1.63 and a fifty-two week high of $127.50.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings data on Friday, November 6th. The company reported ($11.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($8.50) by ($3.14). On average, sell-side analysts forecast that Medicus Pharma will post -33.50 EPS for the current year.

Institutional Investors Weigh In On Medicus Pharma

Large investors have recently bought and sold shares of the company. Private Advisor Group LLC purchased a new stake in shares of Medicus Pharma in the third quarter valued at about $37,000. Sterling Investment Advisors Ltd. acquired a new stake in Medicus Pharma in the 2nd quarter valued at approximately $45,000. Finally, Interchange Capital Partners LLC raised its position in Medicus Pharma by 33.9% in the third quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock valued at $343,000 after purchasing an additional 538,039 shares during the period.

About Medicus Pharma

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes. Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.